<PAGE>
_______________________________________________________________________
_______________________________________________________________________


                                   
                 SECURITIES AND EXCHANGE COMMISSION
                        WASHINGTON, D.C. 20549

              __________________________________________
                                   

                              FORM 8-K
                                   
                            CURRENT REPORT
                 PURSUANT TO SECTION 13 OR 15(d) OF
                 THE SECURITIES EXCHANGE ACT OF 1934

  Date of Report (Date of earliest event reported): November 4, 1996


 _____________________________________________________________________

                    COMMISSION FILE NUMBER 0-17714

 _____________________________________________________________________



                      BIOPOOL INTERNATIONAL, INC.
        (Exact name of Registrant as specified in its charter)




           DELAWARE                                  58-1729436
(State or other jurisdiction of                   (I.R.S. Employer
 incorporation or organization)                  Identification No.)
             




                         6025 NICOLLE STREET
                      VENTURA, CALIFORNIA 93003
               (Address of principal executive offices)
   


                           (805) 654-0643
         (Registrant's telephone number including area code)




_______________________________________________________________________
_______________________________________________________________________
<PAGE>

ITEM 5. OTHER EVENTS

    Reference is made to the press release of Registrant, issued on
November 4, 1996, which contains information meeting the requirements of
this Item 5, and which is incorporated herein by this reference.  A copy
of the press release is attached to this Form 8-K as Exhibit "A."
















































                                  2
<PAGE>
                                  
                                  
                             SIGNATURES
                                  
                                  
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.





Date:       November 8, 1996          BIOPOOL INTERNATIONAL, INC.       
       ___________________________    _________________________________
                                      (Registrant)





                                      /s/ Michael D. Bick, Ph.D.
                                      _________________________________
                                      Michael D. Bick, Ph.D.
                                      Chief Executive Officer and
                                      Chairman of the Board





























                                  3
<PAGE>
                              EXHIBIT A



CONTACTS:    Michael D. Bick, Ph.D.
             Chairman and Chief Executive Officer

             Carol Hill
             Corporate Communications
             (805) 654-0643


FOR IMMEDIATE RELEASE


    BIOPOOL INTERNATIONAL ENTERS INTO AGREEMENT TO ACQUIRE 
      BLOOD GROUP SEROLOGY BUSINESS FROM ORGANON TEKNIKA
                                
                                
VENTURA, California (November 4, 1996)--Biopool International,
Inc. (Nasdaq:BIPL) today announced that it has signed a
definitive Sales and Purchase Agreement to acquire the assets of
the Blood Group Serology (BGS) business from Organon Teknika. 
Organon Teknika is a business unit of Akzo Nobel headquartered in
Arnhem, the Netherlands.  The BGS product line consists of over
75 products used by blood bank facilities located in hospitals,
blood ce nters, and commercial reference laboratories to screen
for specific antibodies and to group and type whole blood.  The
worldwide market for blood serology reagents and RhIG products is
currently estimated to be $435 million.

The BGS product line is sold in over 30 countries worldwide and
is the fourth largest in the U.S., enjoying an approximate 5%
market share.  1996 revenues from BGS products are expected to be
approximately $7 million, nearly doubling Biopool's current
revenue base.

The BGS assets to be acquired include a 36,000 square foot
facility in West Chester, Pennsylvania; approximately 50
employees at that site; 10 outside sales representatives; and
equipment, technology, and certain cell lines associated with the
BGS business.  Sales of Biopool's BGS and hemostasis products in
the U.S. will be carried out by a combined sales force of 12
full-time representatives, working closely with key distributors. 
Outside the U.S., the BGS product line will continue to be
distributed in most countries by the Organon Teknika affiliates
who currently sell those products, pursuant to a two-year 
distribution agreement between Organon Teknika and Biopool.

Michael D. Bick, Ph.D., Biopool's chief executive officer, said,
"We are very excited about the potential offered by this
acquisition.  The BGS product line has a long history of quality



                               4
<PAGE>
Biopool International, Inc.
November 4, 1996
Page 2



and represents a comprehensive product offering to the blood bank
laboratory.  There is a great deal of synergy between the BGS
products and existing Biopool hemostasis products, which we feel
will enable us to promote a more comprehensive product line to
our customers.  In addition, the distribution agreement with
Organon Teknika for non-U.S. sales will assure that there is no
disruption of supply to existing customers for the BGS products,
while at the same time creating exciting opportunities for the
distribution of existing Biopool products, and ultimately,
expansion of our business globally."

Although the purchase agreement contains certain conditions which
must be fulfilled prior to closing, the deal is expected to close
by December 31, 1996.  Although the specific terms of the deal
have not been disclosed, Biopool expects to pay the all-cash
purchase price through debt and possibly equity financing.

Founded in 1987, Biopool International develops, manufactures,
and markets a full range of test kits to assess and diagnose
disorders of blood coagulation, thrombotic risk factors,
fibrinolysis, platelet function, and the vascular system, as well
as specialty chemistry controls used to monitor and measure the
presence of drugs of abuse.  The Company's products are sold to
hospitals and clinical and reference laboratories on a world-wide
basis through an extensive network of distributors.
                                
                              # # #




















                                5
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 6859}]
{"company-data": {"conformed-name": "BIOPOOL INTERNATIONAL INC", "cik": "0000830736", "assigned-sic": "2835", "irs-number": "581729436", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-17714", "film-number": "96658136"}, "business-address": {"street1": "6025 NICOLLE ST SUITE A", "city": "VENTURA", "state": "CA", "zip": "93003", "phone": "8056540643"}, "mail-address": {"street1": "6025 NICOLLE STREET", "city": "VENTURA", "state": "CA", "zip": "93003"}, "former-company": {"former-conformed-name": "CYTRX BIOPOOL LTD", "date-changed": "19890716"}}
_______________________________________________________________________
_______________________________________________________________________

                                   
                 SECURITIES AND EXCHANGE COMMISSION
                        WASHINGTON, D.C. 20549

              __________________________________________
                                   

                              FORM 8-K
                                   
                            CURRENT REPORT
                 PURSUANT TO SECTION 13 OR 15(d) OF
                 THE SECURITIES EXCHANGE ACT OF 1934

  Date of Report (Date of earliest event reported): November 4, 1996

 _____________________________________________________________________

                    COMMISSION FILE NUMBER 0-17714

 _____________________________________________________________________

                      BIOPOOL INTERNATIONAL, INC.
        (Exact name of Registrant as specified in its charter)

           DELAWARE                                  58-1729436
(State or other jurisdiction of                   (I.R.S. Employer
 incorporation or organization)                  Identification No.)
             

                         6025 NICOLLE STREET
                      VENTURA, CALIFORNIA 93003
               (Address of principal executive offices)
   

                           (805) 654-0643
         (Registrant's telephone number including area code)

_______________________________________________________________________
_______________________________________________________________________
ITEM 5. OTHER EVENTS

    Reference is made to the press release of Registrant, issued on
November 4, 1996, which contains information meeting the requirements of
this Item 5, and which is incorporated herein by this reference.  A copy
of the press release is attached to this Form 8-K as Exhibit "A."

                                  2
SIGNATURES
                                  
                                  
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.

Date:       November 8, 1996          BIOPOOL INTERNATIONAL, INC.       
       ___________________________    _________________________________
                                      (Registrant)

                                      /s/ Michael D. Bick, Ph.D.
                                      _________________________________
                                      Michael D. Bick, Ph.D.
                                      Chief Executive Officer and
                                      Chairman of the Board

                                  3
EXHIBIT A

CONTACTS:    Michael D. Bick, Ph.D.
             Chairman and Chief Executive Officer

             Carol Hill
             Corporate Communications
             (805) 654-0643

FOR IMMEDIATE RELEASE

    BIOPOOL INTERNATIONAL ENTERS INTO AGREEMENT TO ACQUIRE 
      BLOOD GROUP SEROLOGY BUSINESS FROM ORGANON TEKNIKA
                                
                                
VENTURA, California (November 4, 1996)--Biopool International,
Inc. (Nasdaq:BIPL) today announced that it has signed a
definitive Sales and Purchase Agreement to acquire the assets of
the Blood Group Serology (BGS) business from Organon Teknika. 
Organon Teknika is a business unit of Akzo Nobel headquartered in
Arnhem, the Netherlands.  The BGS product line consists of over
75 products used by blood bank facilities located in hospitals,
blood ce nters, and commercial reference laboratories to screen
for specific antibodies and to group and type whole blood.  The
worldwide market for blood serology reagents and RhIG products is
currently estimated to be $435 million.

The BGS product line is sold in over 30 countries worldwide and
is the fourth largest in the U.S., enjoying an approximate 5%
market share.  1996 revenues from BGS products are expected to be
approximately $7 million, nearly doubling Biopool's current
revenue base.

The BGS assets to be acquired include a 36,000 square foot
facility in West Chester, Pennsylvania; approximately 50
employees at that site; 10 outside sales representatives; and
equipment, technology, and certain cell lines associated with the
BGS business.  Sales of Biopool's BGS and hemostasis products in
the U.S. will be carried out by a combined sales force of 12
full-time representatives, working closely with key distributors. 
Outside the U.S., the BGS product line will continue to be
distributed in most countries by the Organon Teknika affiliates
who currently sell those products, pursuant to a two-year 
distribution agreement between Organon Teknika and Biopool.

Michael D. Bick, Ph.D., Biopool's chief executive officer, said,
"We are very excited about the potential offered by this
acquisition.  The BGS product line has a long history of quality

                               4
Biopool International, Inc.
November 4, 1996
Page 2

and represents a comprehensive product offering to the blood bank
laboratory.  There is a great deal of synergy between the BGS
products and existing Biopool hemostasis products, which we feel
will enable us to promote a more comprehensive product line to
our customers.  In addition, the distribution agreement with
Organon Teknika for non-U.S. sales will assure that there is no
disruption of supply to existing customers for the BGS products,
while at the same time creating exciting opportunities for the
distribution of existing Biopool products, and ultimately,
expansion of our business globally."

Although the purchase agreement contains certain conditions which
must be fulfilled prior to closing, the deal is expected to close
by December 31, 1996.  Although the specific terms of the deal
have not been disclosed, Biopool expects to pay the all-cash
purchase price through debt and possibly equity financing.

Founded in 1987, Biopool International develops, manufactures,
and markets a full range of test kits to assess and diagnose
disorders of blood coagulation, thrombotic risk factors,
fibrinolysis, platelet function, and the vascular system, as well
as specialty chemistry controls used to monitor and measure the
presence of drugs of abuse.  The Company's products are sold to
hospitals and clinical and reference laboratories on a world-wide
basis through an extensive network of distributors.
                                
                              # # #

                                5